Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Emma Guttman

Showing results (351-360 of 387) with videos related to

Pageof 39
Sort By:
American Journal of Clinical Dermatology|January 22, 2021
Conjunctivitis in Dupilumab Clinical Trials for Adolescents with Atopic Dermatitis or AsthmaAshish Bansal, Eric L Simpson, Amy S Paller, et al.
The Journal of Investigative Dermatology|September 24, 2023
Sclerotic-Type Cutaneous Chronic Graft-Versus-Host Disease Exhibits Activation of T Helper 1 and OX40 CytokinesMadeline Kim, Yael Renert-Yuval, Polina Stepensky, et al.
The New England Journal of Medicine|July 10, 2014
Dupilumab treatment in adults with moderate-to-severe atopic dermatitisLisa A Beck, Diamant Thaçi, Jennifer D Hamilton, et al.
The Journal of Allergy and Clinical Immunology|September 9, 2018
Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitisEmma Guttman-Yassky, Robert Bissonnette, Benjamin Ungar, et al.
Nature Immunology|September 22, 2014
Perivascular leukocyte clusters are essential for efficient activation of effector T cells in the skinYohei Natsuaki, Gyohei Egawa, Satoshi Nakamizo, et al.
The Journal of Allergy and Clinical Immunology|August 9, 2015
Report from the National Institute of Allergy and Infectious Diseases workshop on drug allergyLisa M Wheatley, Marshall Plaut, Julie M Schwaninger, et al.
The Journal of Allergy and Clinical Immunology. in Practice|January 16, 2021
Dupilumab Improves Asthma and Sinonasal Outcomes in Adults with Moderate to Severe Atopic DermatitisMark Boguniewicz, Lisa A Beck, Lawrence Sher, et al.
Lancet (London, England)|May 23, 2021
Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trialsEmma Guttman-Yassky, Henrique D Teixeira, Eric L Simpson, et al.
The Journal of Allergy and Clinical Immunology|September 28, 2016
Early-onset pediatric atopic dermatitis is T<sub>H</sub>2 but also T<sub>H</sub>17 polarized in skinHitokazu Esaki, Patrick M Brunner, Yael Renert-Yuval, et al.
Lancet (London, England)|November 28, 2025
Efficacy and safety of rocatinlimab for the treatment of moderate-to-severe atopic dermatitis in ROCKET-IGNITE and ROCKET-HORIZON: two global, double-blind, placebo-controlled, randomised phase 3 clinical trialsEmma Guttman-Yassky, Kenji Kabashima, Margitta Worm, et al.
Pageof 39

Showing results (351-360 of 387) with videos related to

Sort By:
Pageof 39
American Journal of Clinical Dermatology|January 22, 2021
Conjunctivitis in Dupilumab Clinical Trials for Adolescents with Atopic Dermatitis or AsthmaAshish Bansal, Eric L Simpson, Amy S Paller, et al.
The Journal of Investigative Dermatology|September 24, 2023
Sclerotic-Type Cutaneous Chronic Graft-Versus-Host Disease Exhibits Activation of T Helper 1 and OX40 CytokinesMadeline Kim, Yael Renert-Yuval, Polina Stepensky, et al.
The New England Journal of Medicine|July 10, 2014
Dupilumab treatment in adults with moderate-to-severe atopic dermatitisLisa A Beck, Diamant Thaçi, Jennifer D Hamilton, et al.
The Journal of Allergy and Clinical Immunology|September 9, 2018
Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitisEmma Guttman-Yassky, Robert Bissonnette, Benjamin Ungar, et al.
Nature Immunology|September 22, 2014
Perivascular leukocyte clusters are essential for efficient activation of effector T cells in the skinYohei Natsuaki, Gyohei Egawa, Satoshi Nakamizo, et al.
The Journal of Allergy and Clinical Immunology|August 9, 2015
Report from the National Institute of Allergy and Infectious Diseases workshop on drug allergyLisa M Wheatley, Marshall Plaut, Julie M Schwaninger, et al.
The Journal of Allergy and Clinical Immunology. in Practice|January 16, 2021
Dupilumab Improves Asthma and Sinonasal Outcomes in Adults with Moderate to Severe Atopic DermatitisMark Boguniewicz, Lisa A Beck, Lawrence Sher, et al.
Lancet (London, England)|May 23, 2021
Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trialsEmma Guttman-Yassky, Henrique D Teixeira, Eric L Simpson, et al.
The Journal of Allergy and Clinical Immunology|September 28, 2016
Early-onset pediatric atopic dermatitis is T<sub>H</sub>2 but also T<sub>H</sub>17 polarized in skinHitokazu Esaki, Patrick M Brunner, Yael Renert-Yuval, et al.
Lancet (London, England)|November 28, 2025
Efficacy and safety of rocatinlimab for the treatment of moderate-to-severe atopic dermatitis in ROCKET-IGNITE and ROCKET-HORIZON: two global, double-blind, placebo-controlled, randomised phase 3 clinical trialsEmma Guttman-Yassky, Kenji Kabashima, Margitta Worm, et al.
Pageof 39